Pensionfund Sabic Purchases New Shares in Zoetis Inc. $ZTS

Pensionfund Sabic purchased a new position in Zoetis Inc. (NYSE:ZTS) in the 4th quarter, HoldingsChannel.com reports. The fund purchased 10,500 shares of the company’s stock, valued at approximately $1,321,000.

A number of other large investors also recently added to or reduced their stakes in ZTS. Halbert Hargrove Global Advisors LLC grew its position in shares of Zoetis by 496.6% in the third quarter. Halbert Hargrove Global Advisors LLC now owns 173 shares of the company’s stock valued at $25,000 after purchasing an additional 144 shares during the period. Global Wealth Strategies & Associates acquired a new stake in Zoetis in the 4th quarter worth about $25,000. KERR FINANCIAL PLANNING Corp purchased a new stake in Zoetis during the 3rd quarter worth approximately $31,000. Holos Integrated Wealth LLC purchased a new stake in Zoetis during the 4th quarter worth approximately $32,000. Finally, Board of the Pension Protection Fund acquired a new position in shares of Zoetis during the fourth quarter valued at approximately $38,000. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Zoetis Stock Performance

Zoetis stock opened at $115.94 on Wednesday. The firm has a 50 day simple moving average of $123.97 and a 200-day simple moving average of $129.76. The company has a debt-to-equity ratio of 2.71, a current ratio of 3.03 and a quick ratio of 1.94. The stock has a market cap of $48.94 billion, a price-to-earnings ratio of 19.26, a price-to-earnings-growth ratio of 1.76 and a beta of 0.95. Zoetis Inc. has a 1-year low of $113.30 and a 1-year high of $172.23.

Zoetis (NYSE:ZTS) last posted its earnings results on Thursday, February 12th. The company reported $1.48 EPS for the quarter, beating analysts’ consensus estimates of $1.40 by $0.08. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.The company had revenue of $2.39 billion for the quarter, compared to the consensus estimate of $2.36 billion. During the same quarter in the previous year, the business earned $1.40 earnings per share. The company’s revenue for the quarter was up 3.0% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. On average, analysts expect that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 2nd. Investors of record on Monday, April 20th will be given a dividend of $0.53 per share. The ex-dividend date of this dividend is Monday, April 20th. This represents a $2.12 dividend on an annualized basis and a dividend yield of 1.8%. Zoetis’s dividend payout ratio (DPR) is presently 35.22%.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the company. UBS Group set a $136.00 target price on Zoetis in a research report on Thursday, January 29th. Weiss Ratings upgraded Zoetis from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Thursday, March 12th. Leerink Partners restated a “market perform” rating on shares of Zoetis in a report on Tuesday, March 10th. Barclays initiated coverage on shares of Zoetis in a research note on Monday, December 8th. They set an “equal weight” rating and a $136.00 target price on the stock. Finally, The Goldman Sachs Group upgraded shares of Zoetis to a “buy” rating in a research report on Monday, December 15th. Six research analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the stock. According to data from MarketBeat, Zoetis has a consensus rating of “Hold” and an average price target of $152.91.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.